Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (NZ320006) Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization

Office : New Zealand
Application Number: 320006 Application Date: 22.10.1996
Publication Number: 320006 Publication Date: 21.12.2001
Grant Number: Grant Date: 04.04.2002
Publication Kind : B
Prior PCT appl.: Application Number:PCTAU1996000664 ; Publication Number: Click to see the data
IPC:
A61K 47/36
A61K 48/00
C07K 14/52
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
36
Polysaccharides; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
Applicants: MEDITECH RESEARCH LIMITED
Inventors: Rakoczy, Piroska Elizabeth
Constable, Ian Jeffrey
Agents: AJ PARK
Priority Data: 95 6161 23.10.1995 AU
96 9047 01.04.1996 AU
Title: (EN) Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization
Abstract:
(EN) Patent 320006 A method and composition for gene therapy comprising (a) an adjuvant selected from the group consisting of hyaluronic acid and derivatives thereof; (b) a pharmaceutically-acceptable carrier; and (c) a nucleic acid comprising a polynucleotides selected from the group consisting of a polynucleotides which is antisense to a target polynucleotides and/or a sense polynucleotides encoding a desired specific protein. The composition is suitable for the treatment of retinal diseases caused by neovascularisation.
Also published as:
SG53164EP0859636JP2000507915CN1209068CA2235685KR1019990066967
AU1996072664WO/1997/015330